Opioid Advocacy Transparency Act of 2018
Official title: A bill to amend title XI of the Social Security Act to include additional covered recipients for transparency reports required of manufacturers of opioids.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Read twice and referred to the Committee on Finance.
Opioid Advocacy Transparency Act of 2018
This bill expands reporting requirements related to the ownership and investment interests of certain patient-advocacy organizations.
Under current law, a manufacturer of drugs, devices, or medical supplies that are covered under Medicaid or Medicare must regularly report on any payment or transfer of value by the manufacturer to a "covered recipient," defined as either a physician who is not an employee of the manufacturer or a teaching hospital. The bill expands the definition of "covered recipient," for purposes of this requirement, to also include patient-advocacy organizations that advocate on issues related to opioids. Furthermore, with respect to transfers of value to such organizations, the bill subjects not only manufacturers but also pharmaceutical trade associations to the reporting requirement.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 3565: Opioid Advocacy Transparency Act of 2018. 115th Congress. Open America. https://openamerica.io/bill/115-S-3565/
"S. 3565: Opioid Advocacy Transparency Act of 2018." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-3565/.
S. 3565, 115th Cong. (2026), https://openamerica.io/bill/115-S-3565/.
[S. 3565: Opioid Advocacy Transparency Act of 2018](https://openamerica.io/bill/115-S-3565/)